{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T14:00:16Z","timestamp":1789999216364,"version":"4.0.1"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T00:00:00Z","timestamp":1786579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100001003","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001003","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["PharmacoEconomics Open"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s41669-026-00649-8","type":"journal-article","created":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T14:55:27Z","timestamp":1786632927000},"page":"819-831","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Chronic Kidney Disease Care Model: Quantifying Management Strategies for Improving Patient Outcomes in the USA"],"prefix":"10.1007","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0777-1997","authenticated-orcid":false,"given":"Andrew H.","family":"Briggs","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5516-1862","authenticated-orcid":false,"given":"Ciaran N.","family":"Kohli-Lynch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8966-0966","authenticated-orcid":false,"given":"Adrian R.","family":"Levy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3656-3601","authenticated-orcid":false,"given":"Ziyi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satabdi","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5099-2456","authenticated-orcid":false,"given":"Bonnie M. K.","family":"Donato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8204-911X","authenticated-orcid":false,"given":"Csaba P.","family":"Kovesdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,13]]},"reference":[{"key":"649_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.kisu.2021.11.003","volume":"12","author":"CP Kovesdy","year":"2022","unstructured":"Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl. 2022;12:7\u201311.","journal-title":"Kidney Int Suppl"},{"issue":"5","key":"649_CR2","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1016\/j.kint.2019.07.012","volume":"96","author":"KJ Jager","year":"2019","unstructured":"Jager KJ, et al. A single number for advocacy and communication-worldwide more than 850 million individuals have kidney diseases. Kidney Int. 2019;96(5):1048\u201350.","journal-title":"Kidney Int"},{"key":"649_CR3","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/cvr\/cvad083","volume":"119","author":"C Zoccali","year":"2023","unstructured":"Zoccali C, et al. Cardiovascular complications in chronic kidney disease: a review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association. Cardiovasc Res. 2023;119:2017\u201332.","journal-title":"Cardiovasc Res"},{"key":"649_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/ki.2013.444","volume":"85","author":"A Levin","year":"2014","unstructured":"Levin A, Stevens PE. Summary of KDIGO 2012 CKD Guideline: behind the scenes, need for guidance, and a framework for moving forward. Kidney Int. 2014;85:49\u201361.","journal-title":"Kidney Int"},{"key":"649_CR5","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/j.kint.2023.10.016","volume":"105","author":"A Levin","year":"2024","unstructured":"Levin A, et al. Executive summary of the KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease: known knowns and known unknowns. Kidney Int. 2024;105:684\u2013701.","journal-title":"Kidney Int"},{"key":"649_CR6","doi-asserted-by":"publisher","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","volume":"105","author":"PE Stevens","year":"2024","unstructured":"Stevens PE, et al. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int. 2024;105:S117\u2013314.","journal-title":"Kidney Int"},{"key":"649_CR7","doi-asserted-by":"publisher","first-page":"1864","DOI":"10.1001\/jama.2017.4046","volume":"317","author":"AK Bello","year":"2017","unstructured":"Bello AK, et al. Assessment of global kidney health care status. JAMA. 2017;317:1864\u201381.","journal-title":"JAMA"},{"key":"649_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0271619","volume":"17","author":"DKE Lim","year":"2022","unstructured":"Lim DKE, et al. Prediction models used in the progression of chronic kidney disease: a scoping review. PLoS ONE. 2022;17:e0271619.","journal-title":"PLoS ONE"},{"key":"649_CR9","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/j.kint.2019.01.028","volume":"96","author":"I Schlackow","year":"2019","unstructured":"Schlackow I, et al. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney Int. 2019;96:170\u20139.","journal-title":"Kidney Int"},{"key":"649_CR10","doi-asserted-by":"publisher","first-page":"3380","DOI":"10.1007\/s11606-021-07311-5","volume":"37","author":"RL Tisdale","year":"2022","unstructured":"Tisdale RL, et al. Cost-effectiveness of dapagliflozin for non-diabetic chronic kidney disease. J Gen Intern Med. 2022;37:3380\u20137.","journal-title":"J Gen Intern Med"},{"key":"649_CR11","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1093\/ndt\/gfac280","volume":"38","author":"P McEwan","year":"2022","unstructured":"McEwan P, et al. Extrapolated longer-term effects of the DAPA-CKD trial: a modelling analysis. Nephrol Dial Transplant. 2022;38:1260\u201370.","journal-title":"Nephrol Dial Transplant"},{"key":"649_CR12","doi-asserted-by":"publisher","first-page":"788","DOI":"10.7326\/M22-3228","volume":"176","author":"MM Cusick","year":"2023","unstructured":"Cusick MM, Tisdale RL, Chertow GM, Owens DK, Goldhaber-Fiebert JD. Population-wide screening for chronic kidney disease: a cost-effectiveness analysis. Ann Intern Med. 2023;176:788\u201397.","journal-title":"Ann Intern Med"},{"key":"649_CR13","first-page":"201","volume":"101","author":"JD Lewsey","year":"2015","unstructured":"Lewsey JD, et al. A cardiovascular disease policy model that predicts life expectancy taking into account socioeconomic deprivation. Heart Br Card Soc. 2015;101:201\u20138.","journal-title":"Heart Br. Card. Soc."},{"key":"649_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2014-000140","volume":"3","author":"KD Lawson","year":"2016","unstructured":"Lawson KD, et al. A cardiovascular disease policy model: Part 2-preparing for economic evaluation and to assess health inequalities. Open Heart. 2016;3:e000140.","journal-title":"Open Heart"},{"key":"649_CR15","volume-title":"Cost-effectiveness in health and medicine","year":"2017","unstructured":"Neumann P, Sanders GD, Russell LB, Siegel JE, Ganiats TG, eds. Cost-effectiveness in health and medicine. 2nd edition. Oxford University Press; 2017.","edition":"2"},{"key":"649_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.7326\/M20-1392","volume":"174","author":"DJ Vanness","year":"2021","unstructured":"Vanness DJ, Lomas J, Ahn H. A health opportunity cost threshold for cost-effectiveness analysis in the United States. Ann Intern Med. 2021;174:25\u201332.","journal-title":"Ann Intern Med"},{"key":"649_CR17","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000001377","author":"DS Kazi","year":"2025","unstructured":"Kazi DS, et al. 2025 AHA\/ACC statement on cost\/value methodology in clinical practice guidelines (update from 2014 statement): a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2025. https:\/\/doi.org\/10.1161\/CIR.0000000000001377.","journal-title":"Circulation"},{"key":"649_CR18","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.1093\/ndt\/gfaa364","volume":"36","author":"ME Grams","year":"2020","unstructured":"Grams ME, et al. Clinical events and patient-reported outcome measures during CKD progression: findings from the Chronic Renal Insufficiency Cohort Study. Nephrol Dial Transplant. 2020;36:1685\u201393.","journal-title":"Nephrol Dial Transplant"},{"key":"649_CR19","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/S2213-8587(18)30313-9","volume":"7","author":"J Coresh","year":"2019","unstructured":"Coresh J, et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol. 2019;7:115\u201327.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"649_CR20","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.ekir.2022.01.1067","volume":"7","author":"LR Zelnick","year":"2022","unstructured":"Zelnick LR, et al. Prediction of incident heart failure in CKD: the CRIC study. Kidney Int Rep. 2022;7:708\u201319.","journal-title":"Kidney Int Rep"},{"key":"649_CR21","unstructured":"Annual data report. USRDS. https:\/\/usrds-adr.niddk.nih.gov\/2025. Accessed 11 May 2026."},{"key":"649_CR22","doi-asserted-by":"publisher","unstructured":"United States Life Tables, 2023. https:\/\/stacks.cdc.gov\/view\/cdc\/174591. Accessed 11 May 2026. https:\/\/doi.org\/10.15620\/cdc:118055.","DOI":"10.15620\/cdc:118055"},{"key":"649_CR23","doi-asserted-by":"publisher","unstructured":"National Center for Health Statistics. National vital statistics report, 2025; v. 74, No. 10. https:\/\/stacks.cdc.gov\/view\/cdc\/174607. Accessed 11 May 2026. https:\/\/doi.org\/10.15620\/cdc:107021.","DOI":"10.15620\/cdc:107021"},{"key":"649_CR24","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1002\/ejhf.1594","volume":"21","author":"NR Jones","year":"2019","unstructured":"Jones NR, Roalfe AK, Adoki I, Hobbs FDR, Taylor CJ. Survival of patients with chronic heart failure in the community: a systematic review and meta\u2010analysis. Eur J Heart Fail. 2019;21:1306\u201325.","journal-title":"Eur J Heart Fail"},{"key":"649_CR25","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1177\/2047487312460514","volume":"21","author":"ST Nauta","year":"2014","unstructured":"Nauta ST, Deckers JW, van der Boon RM, Akkerhuis KM, van Domburg RT. Risk factors for coronary heart disease and survival after myocardial infarction. Eur J Prev Cardiol. 2014;21:576\u201383.","journal-title":"Eur J Prev Cardiol"},{"key":"649_CR26","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1001\/jama.2014.7692","volume":"312","author":"S Koton","year":"2014","unstructured":"Koton S, et al. Stroke incidence and mortality trends in US communities, 1987 to 2011. JAMA. 2014;312:259\u201368.","journal-title":"JAMA"},{"key":"649_CR27","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.ejim.2020.11.003","volume":"83","author":"SL Harrison","year":"2021","unstructured":"Harrison SL, et al. End-stage renal disease and 30-day mortality for adults with and without COVID-19. Eur J Intern Med. 2021;83:93\u20135.","journal-title":"Eur J Intern Med"},{"key":"649_CR28","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1186\/s12882-020-01792-y","volume":"21","author":"GA Nichols","year":"2020","unstructured":"Nichols GA, et al. Kidney disease progression and all-cause mortality across estimated glomerular filtration rate and albuminuria categories among patients with vs. without type 2 diabetes. BMC Nephrol. 2020;21:167.","journal-title":"BMC Nephrol"},{"key":"649_CR29","doi-asserted-by":"publisher","first-page":"176","DOI":"10.3111\/13696998.2014.882843","volume":"17","author":"A Ward","year":"2014","unstructured":"Ward A, Alvarez P, Vo L, Martin S. Direct medical costs of complications of diabetes in the United States: estimates for event-year and annual state costs (USD 2012). J Med Econ. 2014;17:176\u201383.","journal-title":"J Med Econ"},{"key":"649_CR30","doi-asserted-by":"publisher","first-page":"S369","DOI":"10.37765\/ajmc.2021.88807","volume":"27","author":"KA Betts","year":"2021","unstructured":"Betts KA, et al. Medical costs for managing chronic kidney disease and related complications in patients with chronic kidney disease and type 2 diabetes. Am J Manag Care. 2021;27:S369\u201374.","journal-title":"Am J Manag Care"},{"key":"649_CR31","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1186\/s12955-020-01559-x","volume":"18","author":"JT Cooper","year":"2020","unstructured":"Cooper JT, et al. Health related quality of life utility weights for economic evaluation through different stages of chronic kidney disease: a systematic literature review. Health Qual Life Outcomes. 2020;18:310.","journal-title":"Health Qual Life Outcomes"},{"key":"649_CR32","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.120.006769","volume":"14","author":"JR Morey","year":"2021","unstructured":"Morey JR, et al. Estimating long-term health utility scores and expenditures for cardiovascular disease from the Medical Expenditure Panel Survey. Circ Cardiovasc Qual Outcomes. 2021;14:e006769.","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"649_CR33","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/hec.910","volume":"14","author":"A Bagust","year":"2005","unstructured":"Bagust A, Beale S. Modelling EuroQol health-related utility values for diabetic complications from CODE-2 data. Health Econ. 2005;14:217\u201330.","journal-title":"Health Econ"},{"key":"649_CR34","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1139\/cjpp-2021-0399","volume":"100","author":"E Gronda","year":"2022","unstructured":"Gronda E, et al. Mechanisms of action of SGLT2 inhibitors and their beneficial effects on the cardiorenal axis. Can J Physiol Pharmacol. 2022;100:93\u2013106.","journal-title":"Can J Physiol Pharmacol"},{"key":"649_CR35","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","volume":"366","author":"C Baigent","year":"2005","unstructured":"Baigent C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366:1267\u201378.","journal-title":"Lancet"},{"key":"649_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-019-0800-z","volume":"21","author":"MMY Lee","year":"2019","unstructured":"Lee MMY, Sattar N, McMurray JJV, Packard CJ. Statins in the prevention and treatment of heart failure: a review of the evidence. Curr Atheroscler Rep. 2019;21:41.","journal-title":"Curr Atheroscler Rep"},{"key":"649_CR37","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","volume":"387","author":"D Ettehad","year":"2016","unstructured":"Ettehad D, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957\u201367.","journal-title":"Lancet"},{"key":"649_CR38","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.326.7404.1427","volume":"326","author":"MR Law","year":"2003","unstructured":"Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ. 2003;326:1427.","journal-title":"BMJ"},{"key":"649_CR39","doi-asserted-by":"publisher","first-page":"1954","DOI":"10.1016\/j.jacc.2021.08.065","volume":"78","author":"CN Kohli-Lynch","year":"2021","unstructured":"Kohli-Lynch CN, et al. Cost-effectiveness of lipid-lowering treatments in young adults. J Am Coll Cardiol. 2021;78:1954\u201364.","journal-title":"J Am Coll Cardiol"},{"key":"649_CR40","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1161\/CIRCULATIONAHA.120.051683","volume":"143","author":"KB Bryant","year":"2021","unstructured":"Bryant KB, et al. Cost-effectiveness of hypertension treatment by pharmacists in Black barbershops. Circulation. 2021;143:2384\u201394.","journal-title":"Circulation"},{"key":"649_CR41","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1236404","volume":"14","author":"X Chen","year":"2023","unstructured":"Chen X, et al. Cardiovascular outcomes and safety of SGLT2 inhibitors in chronic kidney disease patients. Front Endocrinol. 2023;14:1236404.","journal-title":"Front Endocrinol"},{"key":"649_CR42","doi-asserted-by":"publisher","first-page":"2505","DOI":"10.1111\/dom.15122","volume":"25","author":"Y Keidai","year":"2023","unstructured":"Keidai Y, et al. Stabilization of kidney function and reduction in heart failure events with sodium-glucose co-transporter 2 inhibitors: a meta-analysis and meta-regression analysis. Diabetes Obes Metab. 2023;25:2505\u201313.","journal-title":"Diabetes Obes Metab"},{"key":"649_CR43","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2021.14501","volume":"4","author":"N Isaza","year":"2021","unstructured":"Isaza N, et al. Cost-effectiveness of dapagliflozin for the treatment of heart failure with reduced ejection fraction. JAMA Netw Open. 2021;4:e2114501.","journal-title":"JAMA Netw Open"},{"key":"649_CR44","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1177\/0272989X12458348","volume":"32","author":"AH Briggs","year":"2012","unstructured":"Briggs AH, et al. Model parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM modeling good research practices task force working group-6. Med Decis Mak. 2012;32:722\u201332.","journal-title":"Med Decis Mak"},{"key":"649_CR45","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"AH Briggs","year":"2006","unstructured":"Briggs AH, Claxton K, Sculpher MJ. Decision modelling for health economic evaluation. Oxford: Oxford University Press; 2006."},{"issue":"4","key":"649_CR46","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1080\/19345747.2024.2393412","volume":"18","author":"N Dong","year":"2025","unstructured":"Dong N, et al. Advantages of Monte Carlo confidence intervals for incremental cost-effectiveness ratios: a comparison of five methods. J Res Educ Eff. 2025;18(4):951\u201379. https:\/\/doi.org\/10.1080\/19345747.2024.2393412.","journal-title":"J Res Educ Eff"},{"key":"649_CR47","doi-asserted-by":"publisher","first-page":"3168","DOI":"10.1016\/j.jacc.2018.11.002","volume":"73","author":"SM Grundy","year":"2019","unstructured":"Grundy SM, et al. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: executive summary: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. 2019;73:3168\u2013209.","journal-title":"J Am Coll Cardiol"},{"key":"649_CR48","doi-asserted-by":"publisher","first-page":"1303","DOI":"10.1038\/ki.2014.31","volume":"85","author":"C Wanner","year":"2014","unstructured":"Wanner C, Tonelli M, Kidney Disease: Improving Global Outcomes Lipid Guideline Development Work Group Members. KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient. Kidney Int. 2014;85:1303\u20139.","journal-title":"Kidney Int"},{"key":"649_CR49","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1053\/j.ajkd.2023.06.009","volume":"83","author":"M Hannan","year":"2024","unstructured":"Hannan M, et al. Frailty and cardiovascular outcomes in adults with CKD: findings from the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis. 2024;83:208\u201315.","journal-title":"Am J Kidney Dis"},{"key":"649_CR50","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1053\/j.ajkd.2009.09.014","volume":"55","author":"P Muntner","year":"2010","unstructured":"Muntner P, et al. Hypertension awareness, treatment, and control in adults with CKD: results from the chronic renal insufficiency cohort (CRIC) study. Am J Kidney Dis. 2010;55:441\u201351.","journal-title":"Am J Kidney Dis"},{"key":"649_CR51","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1001\/jama.2016.12195","volume":"316","author":"GD Sanders","year":"2016","unstructured":"Sanders GD, et al. Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine. JAMA. 2016;316:1093\u2013103.","journal-title":"JAMA"},{"key":"649_CR52","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1007\/s40273-015-0327-2","volume":"34","author":"P Vemer","year":"2016","unstructured":"Vemer P, Corro Ramos I, van Voorn GAK, Al MJ, Feenstra TL. AdViSHE: a validation-assessment tool of health-economic models for decision makers and model users. Pharmacoeconomics. 2016;34:349\u201361.","journal-title":"Pharmacoeconomics"},{"key":"649_CR53","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1056\/NEJMoa2204233","volume":"388","author":"The EMPA-KIDNEY Collaborative Group","year":"2023","unstructured":"The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. N Engl J Med. 2023;388:117\u201327.","journal-title":"N Engl J Med"},{"key":"649_CR54","doi-asserted-by":"publisher","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","volume":"7","author":"BL Neuen","year":"2019","unstructured":"Neuen BL, et al. SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2019;7:845\u201354.","journal-title":"Lancet Diabetes Endocrinol"},{"key":"649_CR55","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0299401","volume":"19","author":"R Zafarnejad","year":"2024","unstructured":"Zafarnejad R, Chen Q, Griffin PM. Cost-effectiveness of screening for chronic kidney disease using a cumulative eGFR-based statistic. PLoS ONE. 2024;19:e0299401.","journal-title":"PLoS ONE"},{"key":"649_CR56","doi-asserted-by":"publisher","DOI":"10.1080\/0886022X.2024.2406402","volume":"46","author":"M Ramos","year":"2024","unstructured":"Ramos M, et al. Development and validation of a chronic kidney disease progression model using patient-level simulations. Ren Fail. 2024;46:2406402.","journal-title":"Ren Fail"},{"key":"649_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2024.102614","volume":"72","author":"GM Chertow","year":"2024","unstructured":"Chertow GM, et al. Projecting the clinical burden of chronic kidney disease at the patient level (inside CKD): a microsimulation modelling study. EClinicalMedicine. 2024;72:102614.","journal-title":"EClinicalMedicine"},{"key":"649_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0315509","volume":"19","author":"B Slob","year":"2024","unstructured":"Slob B, et al. Cost effectiveness of empagliflozin in adult patients with chronic kidney disease in the Netherlands. PLoS ONE. 2024;19:e0315509.","journal-title":"PLoS ONE"}],"container-title":["PharmacoEconomics - Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00649-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s41669-026-00649-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s41669-026-00649-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T13:02:26Z","timestamp":1789995746000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s41669-026-00649-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,13]]},"references-count":58,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["649"],"URL":"https:\/\/doi.org\/10.1007\/s41669-026-00649-8","relation":{},"ISSN":["2509-4262","2509-4254"],"issn-type":[{"value":"2509-4262","type":"print"},{"value":"2509-4254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,13]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The model relies on published aggregate data sources as detailed in the manuscript and the Supplementary Materials. Individual patient-level data from the Optum Market Clarity database are not publicly available owing to data use agreements.","order":1,"name":"Ethics","label":"Availability of data and material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":2,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable","order":4,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The model is made available under a creative commons noncommercial licence. That licence, the spreadsheet and R versions of the model can be downloaded from the following GitHub repository: OccamResearchLtd\/Pelican-CKD-Care-Modelx4","order":5,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors meet criteria for authorship as recommended by the ICMJE. None of the authors received payment related to the development of the manuscript.\u200b AHB, ARL, SC, BMKD, and CPK conceived and designed the CKD Care model, which was implemented by CNKL and ZL. AHB drafted the manuscript, which was reviewed and adapted by all authors. All authors can take responsibility for the manuscript and approved the final version for submission. Boehringer Ingelheim Pharmaceuticals, Inc. was given the opportunity to review the manuscript for medical and scientific accuracy as well as intellectual property considerations.\u200bPart of the study findings were presented as a poster at the Kidney Week, San Diego, CA, USA, 23\u201327 October 2024.","order":6,"name":"Ethics","label":"Author contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AHB reports consultancy from: Acaster-Lloyd, Astellas, Astra Zeneca, BioCryst Pharma, Bristol Myers Squibb, Boeringher Ingelheim, Chiesi, Daiichi Sankyo, Evidera, Gilead, Galderma, Genmab, GSK, Idorsia, Iveric Bio, Mereo Biopharma, Modex, NIH, Novartis, Parexel, Pfizer , Pharmacosmos, Precision Advisors, Rythmn, Sanofi, Sobi, Takeda, and Teofarma. SC and BMKD are employees of Boehringer Ingelheim Pharmaceuticals Inc. SC has an Adjunct Faculty appointment at the University of Houston College of Pharmacy, Department of Pharmaceutical Outcomes and Policy. ARL, CKL, and ZL have no conflicts to report outside of the submitted work. CPK reports consultancy with: Abbott, Ardelyx, Astra Zeneca, Bayer, Boehringer Ingelheim, Cara Therapeutics, CSL Behring, GSK, Pharmacosmos, ProKidney, Renibus, Takeda. Research funding from: Astra-Zeneca, Bayer, Novartis, CSL Behring, Boehringer Ingelheim. Honoraria from: Abbott, Ardelyx, Astra Zeneca, Bayer, Boehringer Ingelheim, Cara Therapeutics, CSL Behring, GSK, Pharmacosmos, ProKidney, Renibus, and Takeda. Royalties from: UpToDate and Springer. Advisory\/leadership roles as: associate editor:\n                      Diabetes Care\n                      ; editorial board:\n                      Kidney Medicine\n                      ,\n                      Kidney International Reports\n                      ; president elect: International Society of Renal Nutrition and Metabolism.","order":7,"name":"Ethics","label":"Conflicts of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}